article
How dual-targeting ADCs aim to tackle resistance
Find out how dual-target ADCs and tumour-specific Treg depletion are shaping the next wave of targeted cancer therapies.
List view / Grid view
Non-small cell lung cancer (NSCLC)
article
AACR 2025: translating research into real-world impact
From first-in-human trial results to emerging AI tools and patient-focused innovations, AACR 2025 offered a clear snapshot of where cancer research is heading. Drug Target Review was on the ground in Chicago to explore the clinical data, technologies, and conversations shaping cancer drug development.
article
Refining and targeting exatecan with ADC technology
DTR speaks with Dr Patrick van Berkel at ADC Therapeutics to discuss how the company is transforming exatecan delivery to achieve better health outcomes.
article
New therapy shows promise in strengthening CAR-T responses
CAR-T therapy has shown effectiveness in cancer treatment, but relapse often occurs due to limited cell persistence. New strategies aim to improve CAR T-cell durability for longer lasting remission.
article
New targeted therapies show promise in lung cancer treatment
Recent advancements in targeted therapies and immunotherapies are transforming lung cancer treatment. Discover how these innovations are improving outcomes and providing hope for patients.
article
Using AI to predict metastatic behaviour of NSCLC
Dr Richard Cote and Dr Ramaswamy Govindan of the Washington University School of Medicine elucidate how AI, particularly deep learning networks, could identify histopathologic features in non-small cell lung cancer, and impact the treatment approach for early-stage patients.
article
Not all neoantigens are created equal
Founder and CSO of Achilles Therapeutics Dr Sergio Quezada reveals how the landmark TRACERx study has gleaned key insights that could make the difference between success and failure in immunotherapy treatment.
news
Major lung cancer mechanism can be used to evade immune attack
US researchers found high levels of XBP1s in lung cancer cells, which plays a key part in regulating the local immune environment in lung tumours, and can be disabled to increase anti-cancer immunity
article
Telomerase – a universal cancer target for immunotherapeutic vaccines
In this article, Dr Jens Bjørheim, Chief Medical Officer of Ultimovacs, explains why vaccination has proved the best strategy to target human telomerase and why this complex may be an effective approach to combat cancer.
news
Immunotherapy with radiotherapy could improve outcomes of cancers in liver
Researchers have discovered that in mice with cancers in the liver, immunotherapy and radiotherapy prevented T-cell death.
news
New drug target for non-small cell lung cancer identified
A new study has suggested that the enzyme GFPT2 could be a useful target for non-small cell lung cancer (NSCLC).
news
Researchers discover novel cancer immunosuppression mechanism
According to the study, the transcription factor IRF4 drives T cell differentiation and immunosuppression in multiple human cancers.
news
Protein decoy hinders progress of lung cancer growth in mice
Researchers have slowed the spread of a type of non-small cell lung cancer in mice by neutralising a protein that would otherwise cause tumour growth.
article
SEL120: a promising CDK8 kinase inhibitor
A novel CDK8 inhibitor has been developed by scientists at Ryvu Therapeutics. Dr Krzysztof Brzozka showcases this molecule and explains the R&D behind it.
news
Fullerene compounds could be effective therapy against NSCLC
Researchers have used fullerene compounds to cause NSCLC cell death in cell and animal models, which exhibited low toxicity for healthy cells.
